Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

KRYS

Krystal Biotech Inc

May 17 • 09:42AM ET

162.71

Dollar change -1.07
Percentage change -0.65	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VBR VXF IWO IBB SCHA VTWO DFAS

Index	RUT	P/E	86.44	EPS (ttm)	1.88	Insider Own	16.50%	Shs Outstand	28.24M	Perf Week	5.14%
Market Cap	4.65B	Forward P/E	28.83	EPS next Y	5.64	Insider Trans	-4.52%	Shs Float	23.85M	Perf Month	-0.77%
Income	57.16M	PEG	-	EPS next Q	0.76	Inst Own	86.03%	Short Float	10.87%	Perf Quarter	43.27%
Sales	95.95M	P/S	48.43	EPS this Y	579.10%	Inst Trans	0.26%	Short Ratio	6.73	Perf Half Y	63.43%
Book/sh	28.02	P/B	5.81	EPS next Y	113.06%	ROA	8.25%	Short Interest	2.59M	Perf Year	84.50%
Cash/sh	18.85	P/C	8.63	EPS next 5Y	-	ROE	8.87%	52W Range	86.03 - 189.97	Perf YTD	31.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	7.09%	52W High	-14.35%	Beta	0.90
Dividend TTM	-	Quick Ratio	12.42	Sales past 5Y	0.00%	Gross Margin	88.51%	52W Low	89.13%	ATR (14)	6.23
Dividend Ex-Date	-	Current Ratio	12.66	EPS Y/Y TTM	137.44%	Oper. Margin	-57.41%	RSI (14)	51.67	Volatility	3.11% 4.11%
Employees	229	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	59.57%	Recom	1.00	Target Price	193.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	101.81%	Payout	0.00%	Rel Volume	0.22	Prev Close	163.78
Sales Surprise	-4.47%	EPS Surprise	-88.73%	Sales Q/Q	-	Earnings	May 06 BMO	Avg Volume	385.59K	Price	162.71
SMA20	2.57%	SMA50	-2.95%	SMA200	24.30%	Trades		Volume	6,789	Change	-0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Initiated	Goldman	Buy	$160
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$100
Oct-12-23	Initiated	Citigroup	Buy	$160
Sep-07-23	Initiated	Berenberg	Buy	$154
Apr-18-23	Initiated	Stifel	Buy	$102
Feb-28-23	Upgrade	Goldman	Neutral → Buy	$79 → $124
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$74
Jan-18-22	Initiated	BofA Securities	Buy	$110
Jul-20-21	Upgrade	Goldman	Neutral → Buy	$73 → $90
Sep-18-20	Initiated	B. Riley FBR	Buy	$100
Jun-04-20	Initiated	Evercore ISI	Outperform	$90
Sep-24-19	Initiated	Goldman	Neutral	$60
Aug-06-19	Reiterated	H.C. Wainwright	Buy	$56 → $59
Jun-24-19	Reiterated	H.C. Wainwright	Buy	$38 → $56
Jun-24-19	Reiterated	Chardan Capital Markets	Buy	$57.50 → $75
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight	$28

Show Previous Ratings

May-15-24 07:00AM	Krystal Biotech to Present at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-08-24 07:00AM	Krystal Biotech to Present at BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-07-24 11:08AM	Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:03AM	Krystal Biotech Inc (KRYS) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
12:46AM	Q1 2024 Krystal Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
12:53PM	Loading…
May-06-24 12:53PM	KRYS Stock Earnings: Krystal Biotech Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:31AM	Krystal Biotech Inc (KRYS) Surpasses Revenue Estimates in Q1 2024 (GuruFocus.com)
09:10AM	Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates (Zacks)
08:35AM	Krystal Biotech Swings to Q1 Profit -- Shares Fall (MT Newswires)
08:00AM	Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 08:40AM	Why Krystal Biotech (KRYS) Might Surprise This Earnings Season (Zacks)
May-02-24 07:00AM	Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Apr-26-24 07:00AM	Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire)
Apr-23-24 09:35AM	Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround (Zacks)
Apr-22-24 07:00AM	Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung (GlobeNewswire)
08:50AM	Loading…
Apr-17-24 08:50AM	Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Apr-04-24 07:00AM	Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire)
Apr-01-24 08:50AM	Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why (Zacks)
Mar-27-24 07:44AM	3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List (InvestorPlace)
Mar-26-24 07:00AM	Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards (GlobeNewswire)
Mar-14-24 08:50AM	Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-08-24 12:20PM	Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates? (Zacks)
12:00PM	What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock (Zacks)
12:00PM	Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy? (Zacks)
Mar-02-24 12:00AM	Chief Accounting Officer Kathryn Romano Sells 5,000 Shares of Krystal Biotech Inc (KRYS) (GuruFocus.com)
Mar-01-24 07:31AM	2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years (Motley Fool) +5.24%
Feb-28-24 11:07AM	Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-27-24 08:50AM	Here's Why Momentum in Krystal Biotech, Inc. (KRYS) Should Keep going (Zacks) +8.38%
Feb-26-24 11:28PM	Q4 2023 Krystal Biotech Inc Earnings Call (Thomson Reuters StreetEvents) +41.02%
09:25AM	Loading…
09:25AM	Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates (Zacks)
08:31AM	Krystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:00AM	Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 07:00AM	Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 (GlobeNewswire)
Feb-13-24 07:00AM	Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung (GlobeNewswire) -6.17%
Feb-08-24 07:00AM	Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Feb-01-24 07:00AM	Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-24-24 11:01PM	Chief Accounting Officer Kathryn Romano Sells 2,500 Shares of Krystal Biotech Inc (GuruFocus.com)
Jan-04-24 07:00AM	Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK (GlobeNewswire)
Dec-20-23 12:00PM	Krystal Biotech, Inc. (KRYS) Moves to Buy: Rationale Behind the Upgrade (Zacks) -5.20%
Dec-19-23 07:00AM	Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC) (GlobeNewswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-07-23 07:03AM	Here's Why TimesSquare Capital Management U.S. Small Cap Growth Strategy Added Krystal Biotech (KRYS) (Insider Monkey)
Dec-05-23 09:55AM	Wall Street Analysts See a 42.55% Upside in Krystal Biotech, Inc. (KRYS): Can the Stock Really Move This High? (Zacks)
Nov-27-23 07:00AM	Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Nov-21-23 08:21PM	Goldman Sachs Says These 2 Healthcare Stocks Have up to 130% Upside Potential (TipRanks)
Nov-10-23 06:55AM	This Stock Has Quadrupled in 5 Years. Can It Do It Again? (Motley Fool)
Nov-09-23 07:00AM	Krystal Biotech to Present at the Stifel 2023 Healthcare Conference (GlobeNewswire) -6.11%
Nov-07-23 10:26AM	Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.09%
03:22AM	Q3 2023 Krystal Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 08:03AM	Krystal Biotech Inc (KRYS) Announces Q3 2023 Financial Results (GuruFocus.com) -15.05%
07:00AM	Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
07:00AM	Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
Sep-28-23 07:00AM	Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-21-23 09:00AM	Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Sep-13-23 05:01PM	Insider Sell: Suma Krishnan Sells 50,000 Shares of Krystal Biotech Inc (KRYS) (GuruFocus.com)
Sep-07-23 07:00AM	Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-05-23 07:00AM	Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Aug-22-23 11:56AM	Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher (Zacks)
Aug-21-23 11:04AM	Krystal Biotech sells priority review voucher for $100M (American City Business Journals) +5.17%
07:00AM	Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million (GlobeNewswire)
Aug-08-23 06:23AM	We're Interested To See How Krystal Biotech (NASDAQ:KRYS) Uses Its Cash Hoard To Grow (Simply Wall St.) +6.80%
Aug-07-23 07:00AM	Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire) -12.63%
Jul-26-23 06:07PM	Krystal Biotech expands oncology research following FDA acceptance of investigational drug application (American City Business Journals)
04:14PM	Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707 (GlobeNewswire)
Jul-21-23 08:15AM	2 Soaring Stocks With More Upside Potential (Motley Fool)
Jul-17-23 08:50AM	Krystal Biotech, Inc. (KRYS) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-10-23 04:01PM	Arbutus Appoints Two New Executives (GlobeNewswire)
Jul-03-23 07:00AM	Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis (GlobeNewswire)
Jun-28-23 08:30AM	What Will AbbVie Buy Next? (Motley Fool)
Jun-05-23 07:00AM	Krystal Biotech to Present at Upcoming Investor Conferences (GlobeNewswire)
06:44AM	Daily Vickers Top Buyers & Sellers for 06/05/2023 (Argus Research)
Jun-03-23 08:30AM	Up 48% in 2023, Is This Biotech Stock a Buy? (Motley Fool)
May-29-23 12:02PM	Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 41%? (Simply Wall St.)
May-23-23 04:05PM	Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK (GlobeNewswire)
May-22-23 12:53PM	Why Shares of Krystal Biotech Are Rising Monday (Motley Fool) +22.35%
11:05AM	Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10% (Zacks)
10:06AM	FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder (Benzinga)
07:00AM	Krystal Biotech Announces $160 Million Private Placement Equity Financing (GlobeNewswire)
May-19-23 02:03PM	UPDATE 1-U.S. FDA approves Krystal Biotech's skin disorder gene therapy (Reuters) +9.85%
01:57PM	Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa (GlobeNewswire)
May-15-23 04:44AM	Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review (Investing.com)
May-08-23 08:23AM	Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Apr-24-23 07:00AM	Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program (GlobeNewswire)
Apr-18-23 10:07AM	Krystal Biotech, Inc. (NASDAQ:KRYS): When Will It Breakeven? (Simply Wall St.)
07:00AM	Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest (GlobeNewswire)
Apr-13-23 07:00AM	Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting (GlobeNewswire) +6.62%
Mar-06-23 08:09PM	Goldman Sachs Sees Over 60% Upside in These 3 Lesser-Known Stocks Heres Why They Could Jump (TipRanks)
07:00AM	Krystal Biotech Appoints Catherine Mazzacco to Board of Directors (GlobeNewswire)
Mar-03-23 06:38AM	Daily Vickers Top Buyers & Sellers for 03/03/2023 (Argus Research)
Mar-02-23 07:00AM	Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-27-23 07:00AM	Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress (GlobeNewswire)
Feb-21-23 11:14AM	We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely (Simply Wall St.)
Jan-18-23 07:00AM	Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis (GlobeNewswire)
Jan-09-23 03:34PM	Krystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDA (American City Business Journals) -10.91%
08:58AM	Krystal Biotechs stock is down on delayed PDUFA date (MarketWatch)
08:00AM	Krystal Biotech Announces FDAs 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Dec-18-22 06:21PM	The 7 Hottest Biotech Stocks to Own in 2023 and Beyond (InvestorPlace)
Dec-16-22 02:24AM	BofA Securities: The most promising biotech stocks in 2023 (Investing.com)

Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krishnan Suma	President, R&D	Mar 11 '24	Sale	170.96	25,000	4,274,040	1,550,882	Mar 11 08:27 PM
Krishnan Krish S	President and CEO	Mar 11 '24	Sale	170.96	25,000	4,274,040	1,550,882	Mar 11 08:24 PM
Krishnan Krish S	President and CEO	Mar 11 '24	Sale	170.95	25,000	4,273,679	1,612,262	Mar 11 08:24 PM
Krishnan Suma	President, R&D	Mar 11 '24	Sale	170.95	25,000	4,273,679	1,612,262	Mar 11 08:27 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 28 '24	Option Exercise	63.55	7,500	476,625	14,536	Mar 01 08:16 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 28 '24	Option Exercise	31.77	10,000	317,750	17,936	Mar 01 08:20 PM
Krishnan Suma	President, R&D	Feb 28 '24	Option Exercise	0.00	12,500	0	1,643,047	Mar 01 08:13 PM
Krishnan Suma	President, R&D	Feb 28 '24	Option Exercise	0.00	7,500	0	1,579,353	Mar 01 08:13 PM
Krishnan Krish S	President and CEO	Feb 28 '24	Option Exercise	0.00	7,500	0	1,579,353	Mar 01 08:09 PM
Krishnan Krish S	President and CEO	Feb 28 '24	Option Exercise	0.00	12,500	0	1,643,047	Mar 01 08:09 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 28 '24	Sale	166.05	7,500	1,245,381	12,936	Mar 01 08:16 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 28 '24	Sale	165.88	5,000	829,417	12,936	Mar 01 08:20 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 27 '24	Option Exercise	52.26	1,913	99,973	12,936	Feb 28 09:33 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 26 '24	Option Exercise	52.26	8,087	422,627	17,556	Feb 28 09:33 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 26 '24	Sale	136.91	8,087	1,107,180	12,556	Feb 28 09:33 PM
Romano Kathryn	Chief Accounting Officer	Jan 22 '24	Option Exercise	52.26	2,500	130,650	15,056	Jan 24 05:44 PM
Romano Kathryn	Chief Accounting Officer	Jan 22 '24	Sale	130.00	2,500	325,000	12,556	Jan 24 05:44 PM
Krishnan Suma	President, R&D	Dec 11 '23	Sale	105.67	25,000	2,641,663	1,574,206	Dec 12 05:23 PM
Krishnan Krish S	President and CEO	Dec 11 '23	Sale	105.67	25,000	2,641,663	1,574,206	Dec 12 05:17 PM
Krishnan Krish S	President and CEO	Dec 11 '23	Sale	105.67	25,000	2,641,628	1,634,338	Dec 12 05:17 PM
Krishnan Suma	President, R&D	Dec 11 '23	Sale	105.67	25,000	2,641,628	1,634,338	Dec 12 05:23 PM
Krishnan Suma	President, R&D	Sep 11 '23	Sale	127.23	25,000	3,180,841	1,599,206	Sep 12 06:01 PM
Krishnan Krish S	President and CEO	Sep 11 '23	Sale	127.23	25,000	3,180,841	1,599,206	Sep 12 05:59 PM
Krishnan Krish S	President and CEO	Sep 11 '23	Sale	127.23	25,000	3,180,839	1,659,338	Sep 12 05:59 PM
Krishnan Suma	President, R&D	Sep 11 '23	Sale	127.23	25,000	3,180,839	1,659,338	Sep 12 06:01 PM
ORTH ANDREW C.	Chief Commercial Officer	Jun 09 '23	Option Exercise	63.55	12,500	794,375	12,600	Jun 09 07:00 PM
JANNEY DANIEL	Director	Jun 09 '23	Sale	128.77	18,935	2,438,223	107,362	Jun 09 07:03 PM
ORTH ANDREW C.	Chief Commercial Officer	Jun 09 '23	Sale	128.61	12,500	1,607,635	100	Jun 09 07:00 PM
JANNEY DANIEL	Director	Jun 08 '23	Sale	128.11	31,065	3,979,854	126,297	Jun 09 07:03 PM
Krishnan Krish S	President and CEO	May 31 '23	Sale	116.24	25,000	2,905,977	1,684,338	Jun 02 06:21 PM
Krishnan Suma	President, R&D	May 31 '23	Sale	116.24	25,000	2,905,977	1,684,338	Jun 02 06:23 PM
Krishnan Suma	President, R&D	May 31 '23	Sale	116.16	25,000	2,903,912	1,624,206	Jun 02 06:23 PM
Krishnan Krish S	President and CEO	May 31 '23	Sale	116.16	25,000	2,903,912	1,624,206	Jun 02 06:21 PM
Romano Kathryn	Chief Accounting Officer	May 22 '23	Option Exercise	57.91	25,000	1,447,625	25,056	May 23 04:23 PM
Romano Kathryn	Chief Accounting Officer	May 22 '23	Sale	109.04	25,000	2,725,992	12,556	May 23 04:23 PM
Romano Kathryn	Chief Accounting Officer	May 19 '23	Option Exercise	52.26	25,000	1,306,500	28,484	May 23 04:23 PM
JANNEY DANIEL	Director	May 19 '23	Sale	95.02	50,000	4,751,185	157,362	May 23 04:20 PM
Romano Kathryn	Chief Accounting Officer	May 19 '23	Sale	95.05	28,428	2,702,123	12,556	May 23 04:23 PM

Open in Screener

ALLK

Allakos Inc

May 17 • 09:42AM ET

1.36

Dollar change -0.09
Percentage change -6.21	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN FESM VTWO ONEQ IWC VTWV BBC

Index	RUT	P/E	-	EPS (ttm)	-2.45	Insider Own	14.53%	Shs Outstand	87.75M	Perf Week	13.33%
Market Cap	120.41M	Forward P/E	-	EPS next Y	-0.72	Insider Trans	0.00%	Shs Float	75.68M	Perf Month	28.30%
Income	-214.44M	PEG	-	EPS next Q	-0.33	Inst Own	79.97%	Short Float	7.39%	Perf Quarter	8.80%
Sales	0.00M	P/S	-	EPS this Y	28.45%	Inst Trans	63.92%	Short Ratio	10.20	Perf Half Y	-30.96%
Book/sh	1.17	P/B	1.16	EPS next Y	52.82%	ROA	-81.27%	Short Interest	5.59M	Perf Year	-72.91%
Cash/sh	1.57	P/C	0.86	EPS next 5Y	26.70%	ROE	-111.56%	52W Range	0.98 - 5.64	Perf YTD	-50.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.51%	ROI	-151.67%	52W High	-75.89%	Beta	0.96
Dividend TTM	-	Quick Ratio	4.11	Sales past 5Y	0.00%	Gross Margin	-	52W Low	38.79%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	4.11	EPS Y/Y TTM	-1.12%	Oper. Margin	0.00%	RSI (14)	60.49	Volatility	10.24% 8.42%
Employees	131	Debt/Eq	0.39	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.50	Target Price	2.90
Option/Short	Yes / Yes	LT Debt/Eq	0.36	EPS Q/Q	-63.58%	Payout	-	Rel Volume	0.78	Prev Close	1.45
Sales Surprise	-	EPS Surprise	-83.22%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	548.51K	Price	1.36
SMA20	18.47%	SMA50	12.79%	SMA200	-33.60%	Trades		Volume	33,998	Change	-6.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-17-24	Downgrade	Jefferies	Buy → Hold	$6 → $1.50
Jan-16-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-18-23	Upgrade	William Blair	Mkt Perform → Outperform
Dec-08-23	Resumed	Jefferies	Buy	$9 → $6
Sep-27-23	Initiated	JMP Securities	Mkt Outperform	$11
May-12-23	Upgrade	Jefferies	Hold → Buy	$6 → $9
Mar-07-23	Initiated	Piper Sandler	Overweight	$22
Sep-12-22	Downgrade	SMBC Nikko	Neutral → Underperform	$2
Dec-22-21	Downgrade	William Blair	Outperform → Mkt Perform
Dec-22-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$17
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Dec-22-21	Downgrade	Cowen	Outperform → Market Perform
Dec-22-21	Downgrade	BofA Securities	Buy → Underperform	$155 → $12
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight	$88
Jul-15-21	Initiated	Cowen	Outperform
May-18-21	Initiated	H.C. Wainwright	Buy	$230
Feb-24-21	Initiated	Cantor Fitzgerald	Overweight	$218
Jan-15-21	Initiated	BofA Securities	Buy	$145
Dec-21-20	Initiated	SVB Leerink	Outperform	$150
Feb-27-20	Initiated	Barclays	Underweight	$36

Show Previous Ratings

May-10-24 04:02PM	Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions (GuruFocus.com) -6.98%
May-09-24 10:56PM	ALLK Stock Earnings: Allakos Meets EPS for Q1 2024 (InvestorPlace)
04:02PM	Allakos Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-03-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +5.45%
Apr-09-24 06:31AM	3 Biotech Stocks to Dump Before They Go to Zero (InvestorPlace) +6.19%
08:36AM	Loading…
Apr-04-24 08:36AM	Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Mar-16-24 05:31AM	Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4 (GuruFocus.com)
Mar-14-24 09:54PM	ALLK Stock Earnings: Allakos Misses EPS for Q4 2023 (InvestorPlace) -6.45%
04:02PM	Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 07:02AM	Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 (GlobeNewswire) +7.35%
Feb-12-24 07:02AM	Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition (GlobeNewswire)
Jan-18-24 09:35AM	Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks (Zacks) +6.86%
Jan-17-24 12:10PM	Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug (Zacks) -14.29%
Jan-16-24 11:36AM	Why Is Allakos (ALLK) Stock Down 57% Today? (InvestorPlace) -60.20%
09:40AM	Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:28AM	Loading…
09:28AM	Allakos drops lead asset after midphase flops join litany of letdowns, halves headcount (FierceBiotech.com)
07:27AM	UPDATE 2-Allakos tumbles after skin disease drug fails mid-stage studies (Reuters)
07:17AM	Allakos says experimental skin disease drug fails mid-stage studies (Reuters)
07:02AM	Allakos Announces a Restructuring to Focus on Development of AK006 (GlobeNewswire)
07:00AM	Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints (GlobeNewswire)
05:09AM	Allakos to lay off half of staff, scrap drug after study setback (BioPharma Dive)
Nov-13-23 05:01PM	Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023 (GuruFocus.com)
04:02PM	Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-27-23 12:10PM	Why Shares of Allakos Are Up Wednesday (Motley Fool) +15.74%
Aug-30-23 04:05PM	Allakos Appoints Neil Graham to its Board of Directors (GlobeNewswire)
Aug-09-23 04:02PM	Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) -9.09%
Aug-02-23 04:05PM	Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors (GlobeNewswire)
08:20AM	Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth (Simply Wall St.)
Jun-12-23 07:02AM	Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition (GlobeNewswire)
Jun-05-23 07:02AM	Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023 (GlobeNewswire)
08:05AM	Loading…
May-13-23 08:05AM	Allakos Inc. (NASDAQ:ALLK) has caught the attention of institutional investors who hold a sizeable 45% stake (Simply Wall St.)
May-12-23 05:00PM	Why Allakos Stock Skyrocketed Nearly 9% Higher Today (Motley Fool) +8.89%
May-09-23 04:02PM	Allakos Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-07-23 04:05PM	Why Allakos Stock Was Heating Up Today (Motley Fool) +21.30%
Mar-06-23 04:02PM	Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -6.90%
Jan-26-23 05:33AM	Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value (Simply Wall St.)
Dec-15-22 11:35AM	Is Allakos (NASDAQ:ALLK) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Dec-09-22 12:00PM	Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-29-22 07:02AM	Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology (GlobeNewswire) +7.88%
Nov-10-22 09:02AM	Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancers 37th Annual Meeting (GlobeNewswire) +5.86%
Nov-07-22 04:05PM	Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-14-22 06:35PM	Alkermes, Allakos, and Other Stocks See Action From Activist Investors (Barrons.com) -9.74%
Sep-30-22 11:48AM	3 Healthcare Stocks to Sell Before They Die (InvestorPlace) +9.29%
Sep-24-22 08:32AM	After losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gain (Simply Wall St.)
Sep-19-22 07:00AM	Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire) +27.51%
Sep-12-22 07:02AM	Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Sep-09-22 08:47AM	After Disappointing Data, Allakos Discontinues Work On Lirentelimab In Eosinophilic Gastrointestinal Diseases (Benzinga) +5.71%
07:00AM	Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis (GlobeNewswire)
Aug-31-22 02:10PM	Why Allakos Stock Is on Fire Today (Motley Fool) +20.05%
Aug-04-22 04:04PM	Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-25-22 04:05PM	Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors (GlobeNewswire)
Jul-08-22 10:18AM	Companies Like Allakos (NASDAQ:ALLK) Could Be Quite Risky (Simply Wall St.)
May-06-22 04:05PM	Allakos Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
Apr-28-22 06:00PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-19-22 06:15PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-12-22 06:15PM	Allakos Inc. (ALLK) Gains As Market Dips: What You Should Know (Zacks)
Apr-09-22 10:03AM	How Much Of Allakos Inc. (NASDAQ:ALLK) Do Institutions Own? (Simply Wall St.)
Mar-28-22 06:15PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-22-22 06:15PM	Allakos Inc. (ALLK) Outpaces Stock Market Gains: What You Should Know (Zacks)
Mar-15-22 06:00PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-07-22 10:39AM	Why Allakos Stock Sank 17.3% in February (Motley Fool)
Mar-03-22 11:05AM	After clinical trial failures, Peninsula drug developer opts to cut 35% of jobs (American City Business Journals)
Mar-01-22 04:05PM	Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-25-22 06:00PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Feb-21-22 09:53AM	Allakos (ALLK) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-17-22 02:38AM	Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey) -8.28%
Feb-08-22 01:38PM	Handelsbanken Fonder AB Buys FREYR Battery, Pfizer Inc, GXO Logistics Inc, Sells SVB Financial ... (GuruFocus.com)
Feb-07-22 01:38PM	Silvant Capital Management LLC Buys Netflix Inc, Pfizer Inc, Natera Inc, Sells Visa Inc, ... (GuruFocus.com)
Feb-04-22 06:00PM	Allakos Inc. (ALLK) Flat As Market Gains: What You Should Know (Zacks)
Feb-01-22 01:38PM	BCGM Wealth Management, LLC Buys PowerShares QQQ Trust Ser 1, Apple Inc, First Merchants Corp, ... (GuruFocus.com)
08:00AM	Allakos to Host Investor Day on February 15 (GlobeNewswire)
Jan-24-22 06:15PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
01:53PM	5 Important Investing Lessons From Allakos Price Collapse (InvestorPlace)
Jan-12-22 12:09PM	Allakos Is a Cautionary Tale of Biopharmaceutical Investing (InvestorPlace)
Jan-09-22 06:26AM	We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate (Simply Wall St.)
Jan-06-22 08:17AM	Why Allakos Stock Plummeted 87.5% in the Last Month of 2021 (Motley Fool)
Jan-05-22 06:59AM	After a Clinical-Data Bombshell, Allakos Might Actually Be a Buy (InvestorPlace)
Jan-04-22 10:00AM	Down 86.1% in 4 Weeks, Here's Why Allakos Inc. (ALLK) Looks Ripe for a Turnaround (Zacks) -7.44%
09:40AM	Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year? (Zacks)
Dec-22-21 04:37PM	Peninsula biotech sheds 90% of stock value after drug trials flop (American City Business Journals) -89.87%
12:36PM	ALLK Stock Alert: Why Is Allakos Absolutely Plunging Today? (InvestorPlace)
10:41AM	Why Allakos Stock Is Crashing Today (Motley Fool)
09:07AM	Tesla's Rising, but This Nasdaq Biotech Stock Got Absolutely Crushed Wednesday (Motley Fool)
Dec-21-21 07:15PM	Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases (GlobeNewswire)
Dec-20-21 08:32AM	Implied Volatility Surging for Allakos (ALLK) Stock Options (Zacks)
Dec-08-21 07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... (GuruFocus.com)
07:38PM	Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ... (GuruFocus.com)
Nov-30-21 07:00AM	Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma (GlobeNewswire)
Nov-19-21 10:27AM	Ohio Capital Fund to keep using tax credits; Columbus startup Aware a bright spot in portfolio (American City Business Journals)
08:40AM	Do Options Traders Know Something About Allakos (ALLK) Stock We Don't? (Zacks)
Nov-08-21 04:05PM	Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-25-21 08:00AM	Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation (GlobeNewswire)
Oct-24-21 03:35PM	Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting (GlobeNewswire)
Sep-30-21 11:12AM	Notable Allakos Insider Trades $435K In Company Stock (Benzinga)
08:39AM	Implied Volatility Surging for Allakos (ALLK) Stock Options (Zacks)
Sep-29-21 08:47AM	15 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey)
Aug-09-21 04:01PM	Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-29-21 05:31PM	15 Stocks that Will Double In 2021 (Insider Monkey)
Jul-21-21 06:44AM	3 Biotech Stocks That Could Double Soon (Motley Fool)
Jul-13-21 01:32AM	Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth (Simply Wall St.) -5.54%

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

KRYS

Krystal Biotech Inc

ALLK

Allakos Inc

Upgrade your FINVIZ experience